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Abstract
This review considers the detection and management of early HIV infection (EHI), defined here as
the first 6 months of infection. This phase is clinically important because a reservoir of infected
cells formed in the individual renders HIV incurable, and the magnitude of viremia at the end of
this period predicts the natural history of disease. Epidemiologically, it is critical because the very
high viral load that typically accompanies early infection also makes infected individuals
maximally contagious to their sexual partners. Future efforts to prevent HIV transmission with
expanded testing and treatment may be compromised by elevated transmission risk earlier in the
course of HIV infection, although the extent of this impact is yet unknown. Treatment as
prevention efforts will nevertheless need to develop strategies to address testing, linkage to care,
and treatment of EHI. Cost-effective and efficient identification of more persons with early HIV
will depend on advancements in diagnostic technology and strengthened symptom-based
screening strategies. Treatment for persons with EHI must balance individual health benefits and
reduction of the risk of onward viral transmission. An increasing body of evidence supports the
use of immediate antiretroviral therapy to treat EHI to maintain CD4 count and functionality, limit
the size of the HIV reservoir, and reduce the risk of onward viral transmission. Although we can
anticipate considerable challenges in identifying and linking to care persons in the earliest phases
of HIV infection, there are many reasons to pursue this strategy.
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The goals of immediate antiretroviral therapy (ART) for individuals presenting with early
HIV infection (EHI) are twofold: first, for the health benefits of the individual and second to
reduce the risk of onward viral transmission. Use of ART to control the HIV epidemic has
garnered considerable interest at the population level. The extent to which elevated
transmission during EHI1—if not reached by treatment—might compromise the preventive
effect is a matter of debate.2–5
The evidence to date about the feasibility of treatment as prevention targeting persons with
EHI are summarized in Table 1. This review synthesizes the existing evidence on the
individual-level effects of early treatment and its potential role in using ART to prevent HIV
transmission. Specifically, we consider the significance of early treatment in 3 areas: the
challenges of finding early infection, in moderating essential behavior change in these
individuals, and considerations for treatment of those with EHI.
EARLY HIV INFECTION
Sexual transmission of HIV generally involves only 1 or a small number of viral variants
infecting receptive cells.6,7 The earliest days of infection are marked by HIV replication in
the mucosa, submucosa, and lymphoreticular tissues, during which viral markers can only be
detected in the affected tissues but not in the plasma.8 Once HIV RNA concentration
increases to 1–5 copies per milliliter in plasma, nucleic acid amplification can be used to
qualitatively detect HIV, after which the sequential appearance of various viral makers
define the stages of EHI for which different quantitative clinical assays can be used to
monitor viral load.9 At the same time, the initial immune response includes a “cytokine
storm” that in a substantial number of newly infected people produces acute retroviral
syndrome10 and that can be used to mark the stages of acute infection.11
Gut T-cell depletion12 and rapid growth in the HIV DNA reservoir size13,14 take place in the
earliest (first ~25 days) after infection.15 However, elevated risk of transmissions has been
shown to persist for up to 6 months after seroconversion.16 “Early HIV infection” here will
therefore refer to all stages of acute infection including seroconversion and up until the
establishment of early chronic infection, approximately 3–6 months after HIV acquisition.
This stage of infection is critical both clinically and epidemiologically because (1) the
reservoir of infected cells is formed in the individual that render HIV incurable; (2) the
magnitude of viremia at set point predicts the natural history of disease,17 and (3) the very
high viral load that typically accompanies acute infection—combined with specific
characteristics of recently transmitted viral variants18—can make acutely infected
individuals maximally contagious to their sexual partners.9
HIV AND THE SPREAD OF INFECTION
The biological plausibility of elevated HIV transmission risk during EHI is based on the
heightened viral load of persons with early infection—often on the order of 106 log copies
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per milliliter19—which is also mirrored in high levels of virus in the genital tract.19–21 In
addition, characteristics of the transmitted virus,18 concomitant sexually transmitted
infections,22 and patterns of sexual behavior among recently infected individuals23 who may
be unaware of their status24 may all factor into the role that EHI plays in the spread of HIV.
However, the extent to which HIV treatment as prevention programs must account for
transmission during EHI is a matter of some debate.5,25
The biological plausibility that EHI may enhance transmission risk is supported in some risk
groups by the findings of phylogenetic methods to define transmission clusters22,26–28 or
reconstruct transmission events during EHI29 using viral sequences from recently infected
persons. Results suggest that HIV transmission from persons with EHI may account for
25%–50% of all viral transmissions within certain populations.16,26,29 Some posit, however,
that the failure of these methods to consider other risk factors for transmission or to
distinguish between new and chronic infection may lead them to overestimate the portion of
new infections attributable to EHI.30
Mathematical models also provide insight into the role of EHI in HIV epidemiology. As we
have summarized previously,9,31 model estimates of the contribution of EHI to population-
level transmission have varied widely, with estimates of the portion of new cases
attributable to EHI ranging from 1% to 82% (Table 2), depending on epidemic stage, model
structure, assumptions about sexual contact rates and patterns, and the assumed duration of
high infectiousness associated with EHI. We are aware of only one model to date that has
formally assessed the potential impact of prevention interventions during EHI,25 the results
of which suggest that transmission prevention during both EHI and chronic infection are
needed for maximal impact.
IDENTIFYING EHI
Successful use of ART during EHI to control the HIV epidemic will depend greatly on our
ability to effectively screen and identify these individuals to target for intervention, although
this is not yet part of routine testing strategies. Such efforts will likely demand more
frequent testing, particularly among those believed to be at greater risk of HIV infection and
with the use of novel tools such as self-administered HIV tests—where legally
sanctioned47—paired with open access to care. The acute phase of EHI when antibodies are
not yet present will remain undetected by traditional antibody tests,48–50 when diagnosis
must rely on direct detection of virus using nucleic acid amplification tests or viral antigen
such as p24. Give the financial, technical, and logistical barriers to widespread use of
nucleic acid amplification tests, third- and fourth-generation indirect enzyme immunoassays
have emerged as a strong alternative. The sensitivity of these tests to HIV antibody isotypes
that emerge earlier in the course of infection (IgM and IgG), and in the case of fourth
generation to p24 antigen, allow detection earlier in the course of infection with relatively
good sensitivity.3–5,49,51 However, limited availability of fourth-generation enzyme
immunoassays in resource poor settings and low sensitivity for detecting HIV infection
before seroconversion limits their utility in many settings with high EHI prevalence.52,53
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Pooling samples for batched RNA screening may be a cost-effective alternative for EHI
detection in places with higher prevalence of persons with EHI,6,7,49,54–58 but laboratory-
based assays remain costly, necessitate people attending for testing venipuncture, and
require patient follow-up. Field evaluations of available point-of-care tests to date have
reported disappointingly high false-positive and false-negative rates.1,9,59,60
In light of these shortcomings, symptom-based screening—particularly those that
incorporate targeted screening—must be developed as a cornerstone of field efforts to
identify persons with EHI. Candidate populations include those presenting with symptoms
indicative of sexually transmitted infections2–5,61,62 or with reported high-risk
behavior.6,7,11,50,62 A strengthened symptom-based screening strategy will also require
retraining of clinicians and community health workers, paired with routinized point-of-care
viral load testing.63
PREVENTION IN PERSONS WITH EHI
Beyond the limitations of timely and adequate identification of acutely infected individuals
are the unique challenges of preventing the HIV transmission in these individuals.
Behavioral interventions will demand swift and decisive strategies to reduce risk behaviors,
including notification of current sexual partners, limitation of new partner acquisition,
condom use, and, possibly, abstinence during the acute phase. Seeking behavior change is
the most constant theme in HIV prevention, but the limited evidence available on behavior
change during EHI9,64,65 bode less well for future interventions in persons with EHI.
Following the biological plausibility of reduced viremia leading to reduced HIV
transmission risk,66,67 we expect that treated persons with EHI will be less likely to transmit
to their partners. In the absence of a mechanism to directly observe this effect, the
phylogenetic cluster study by Rieder et al on transmission dynamics in gay men in
Switzerland suggests that at least 5 reconstructed transmission events were attributable to
presumed transmitters who ceased early therapy.68 Although discouraging from a disease
control standpoint, these findings also underscore the need for new ways to modify and
measure the impact of early ART on HIV transmission in persons with EHI.
THERAPEUTIC EFFECTS OF EARLY ART
The rationale for treating individuals with EHI is based on the suppressive effect of ART on
patient viral load, which consistent of 4 elements: (1) alleviation of symptoms of early
infection, (2) preservation of immune function, (3) reduction in the viral reservoirs, and (4)
reduction of HIV transmission during EHI.
Until more recent evidence to the contrary,15,69 early exposure to ART was considered
something best avoided or at least be administered intermittently so as to minimize
cumulative side effects or the development of drug resistance.16,70 Here, we summarize
findings from the body of literature reporting treatment effects of ART—defined as 1 to 4
antiretroviral drugs in a regimen—administered as either consistent or intermittent courses
—during all phases of EHI (Table 3).
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Early ART Alleviates Acute Syndrome Symptoms
Acute retroviral syndrome can manifest within days to weeks after exposure, as mildly as a
viral syndrome or as severely as multisystem dysfunction.18,116–118 By reducing viral levels
in treated patients, ART can modify both the direct viral effect and the host immune
response to the virus, thereby alleviating symptoms of acute infection.9,27,68,96 Treatment
for the sole purpose of reducing these symptoms was included as an indication for treatment
for individuals with EHI in a recent set of treatment guidelines in the United Kingdom.63
Effect of ART in EHI on Immune Function
There is little debate about the role of immediate ART for individuals presenting with very
low initial CD4 counts or who are severely unwell,19–21,119 but there is some uncertainty
about appropriate courses for those identified in EHI with only minor symptoms and high
CD4 counts. Known immunological benefits of ART initiated during EHI to date fall into 2
general categories: slower disease progression and near-term improvements in HIV-specific
immunological responses.
Regarding disease progression, numerous observational studies and 7 randomized clinical
trials have identified associations between early ART and the slowing of the depletion of
CD4+ T cells77,83–86,90–92,99,102,106,107 as well as with the facilitation of immune cell
restoration.22,80,92,94 Preservation of immune cell function has also been
reported23,95,100,108,112 but not universally.24,115 In many of these studies, ART exposure
was very brief and longitudinal follow-up time relatively short, limiting the strength of
inferences that can be drawn about early treatment.
ART during EHI has also been associated with improved HIV-specific T-cell
function,5,25,73,89,96,100,110 although starting ART too early may possibly interfere with the
initial HIV-specific humoral response.115 Persistent immune activation has been identified
among early ART initiators,29,75,81,112,113 possibly to a lesser extent than persons starting
ART during chronic infection.16,26,29,88
Taken together, these data suggest that immediate use of ART irrespective of CD4 count
could be expected to confer health benefits to patients with HIV. However, the durability
and magnitude of these effects are yet unknown, limiting their immediate application to
clinical decisions regarding optimal management of persons with EHI. Future research
efforts must take note that increasingly higher CD4 thresholds for ART initiation in
guidelines will continue to narrow the gap between early and delayed therapy, necessarily
limiting our ability to decisively attribute observed health effects to early therapy.30,48–50,95
Effect of ART in EHI on Virological Outcomes
In addition to improvements in surrogate markers of clinical progression, studies report
potential benefits of ART during EHI on virological outcomes. The potential effect of ART
on the viral set point—the level at which a patient’s viral load stabilizes after seroconversion
—is of great interest given its strong association with the course of disease progression.120
Two observational studies101,109 and several trials83,87,104 have examined this issue, all but
one101 reporting lower viral set points among patients treated during EHI versus those who
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were not. The variable definitions of viral set point across these studies, defined as the viral
load at points in time ranging from 7 to 72 weeks after ART cessation, and the
noncomparability of controls may contribute to the inconsistency of results across
observational studies.87,104,109 Nevertheless, the fact that 3 randomized clinical
trials87,104,107 all demonstrated some reduction in viral set point between ART-treated and
control participants suggest the presence of a substantive effect.
Although some report no effect of transient therapy on virological indicators after
cessation,92,101,113 most identify a significant difference in the viral loads of the early
treatment groups74,77,80,84,95,96,99,107,110,114 versus their comparators. Interruption of ART
almost invariably leads to the reemergence of detectable viral replication and the
progression of HIV infection, a result of the establishment of inaccessible viral reservoirs.121
Finally, very early treatment may impact the size of the latent reservoir that is established
early after infection. Research in this area may be critical for future work on HIV cure,71,105
the key barrier to which is eradication of the latent pool of inaccessible reservoir cells.122 To
date, results of 4 separate study groups provide the most insight. The RV254/SEARCH 010
Study Group has reported that ART during EHI may play a key role in immune restoration
and preventing the seeding of the HIV reservoir in the gut mucosal tissue of 20 Thai
participants.15 These findings are supported by other groups who also report reduction in the
sizes of viral reservoirs—measured as levels of cell-associated HIV DNA—among
individuals with EHI receiving immediate ART compared with deferred therapy,75,85,88,123
in some cases even to levels comparable with those of documented elite controllers.124
Examining perhaps the most rigorous measure of the persistent HIV reservoir, resting CD4
cell infection with replication competent virus, Archin et al observed a strong correlation
between the extent of viral replication before suppressive ART and the size of the resting
cell reservoir.71 The Virological and Immunological Studies in Controllers after Treatment
Interruption group demonstrated that early ART could also enhance viral control of therapy
irrespective of HLA type and CCR5 genotype in a subset of patients treated intermittently
during early infection.72,81,125 This group showed that immediate ART initiated within 12
weeks of diagnosis and maintained for a minimum of 3.5 years before discontinuing was
associated with a higher proportion of viral controllers several years after stopping ART
compared with the proportion of controllers described in untreated chronic infection (from
<1% to 15.6%).
These findings together with the successful elimination of HIV from 1 patient126 and the
functional cure reported in an infant treated at birth127 give cautious hope to the concept of
strategic use of ART to limit establishment or reestablishment of the viral reservoir and
work toward HIV cure.
Other Considerations of Early ART
A successful strategy to carry out early ART for prevention purposes must address a
complex interplay of factors likely to mediate its impact. The acceptability of such a strategy
must, for example, help patients faithfully confront the reality of lifelong adherence from an
earlier stage in the course of disease, with which we have limited experience. Our
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understanding of the toxicity of prolonged exposure to antivirals for even longer duration is
also limited.86
The choice of ART regimens will also determine the success of treatment as prevention
strategies targeting persons with EHI. Current regimens are designed for simplicity, reduced
cost, tolerance, patient and clinician preference, and the genotype of transmitted virus.
However, for persons with EHI, treatment choices may be informed by patients’ desires to
initiate therapy as soon as possible—often before resistance data are available—and the
inclusion of agents known to achieve rapid decreases in plasma viral load. Selecting drugs
that concentrate in the genital or gastrointestinal tracts, such as integrase inhibitors, may
protect lymphocytes in these compartments that are especially vulnerable to the adverse
effects of EHI and also present clear prevention advantages. Evidence that intensive drug
regimens of up to 5 agents may confer benefit over standard triple therapy for individuals
with EHI is still formative.96
The potential risks of earlier initiation of ART can be, in part, anticipated, given the
anticipated risks of lifelong treatment for all patients with HIV. Early ART may present new
challenges for effective delivery of patient care, but may also have positive impacts on
patient quality of life82 and retention in care.128 But the relatively short follow-up periods,
transient nature of the treatment exposure, and small sample sizes limit insight and
underscore the need for further research into comparative treatment outcomes.129
Furthermore, interruption of therapy has been associated with major cardiovascular, renal,
and hepatitic disease,69 outcomes that must be considered when bearing risks versus benefits
of sustained therapy.
Finally, as with all treatment as prevention efforts, feasibility of future programs must
anticipate logistical challenges such as drug stock-outs or unavailability of second-line
regimens.130
SUMMARY AND CONCLUSIONS
The formative nature of research into ART during EHI is reflected in the lack of consensus
surrounding treatment guidelines for these persons. The United States and United Kingdom
are the only 2 countries known to date with specific guidelines for clinical management of
disease in persons with EHI.63,130–132 In both cases, treatment is recommended, though both
note caveats about the strength of evidence.
However, an increasing body of evidence supports the role of immediate ART among
individuals identified with EHI to facilitate immune function, limit the size of the HIV
reservoir, and reduce the risk of onward viral transmission. We and others have anticipated
the considerable difficulty in finding subjects in the earliest phases of HIV infection given
the added demands of repeat HIV testing, limitations of detection using currently available
technologies, and the need for enhanced provider and patient awareness of the clinical and
prevention significance of EHI. These considerations notwithstanding, future HIV control
efforts will need to emphasize novel and targeted methods to identify patients with EHI and
provide unequivocal support for treatment to improve their quality of life and limit onward
transmission of HIV.
Smith et al. Page 7























K.S. was supported by the National Institute of Allergy and Infectious Diseases T32 training grant, T32 AI0700.
W.C.M., K.A.P., and S.E.R. were supported by the US National Institutes of Health grant R01 AI083059 and SER
by R01 IF30MH085431. S.F. received funding from the National Institute for Health Research Imperial Biomedical
Research Center (P46467), FHI360 (0800 0166/964), and the London School of Hygiene & Tropical Medicine
(EPIDVH72). M.S.C. and J.J.E. received funding from the University of North Carolina Center for AIDS Research
(P30 AI50410), the HIV Prevention Trials Network (UM1 AI068619), and the National Institute of Diabetes and
Digestive and Kidney Diseases R37 DK049381. The funders had no role in the study design, data collection and
analysis, decision to publish, or preparation of the manuscript.
S.F. has grants/grants pending and has received payment as a speaker. K.A.P. receives salary support from the
National Institutes of Health. J.J.E. is an ongoing consultant with Merck, GSK, WiiV, Gilead, BMS, and Janssen
and has grants/grants pending with Merck, GSK, and BMS.
References
1. Cates W, Chesney MA, Cohen MS. Primary HIV infection—a public health opportunity. Am J
Public Health. 1997; 87:1928–1930. [PubMed: 9431278]
2. Epstein H. Universal voluntary HIV testing and immediate antiretroviral therapy. Lancet. 2009;
373:1078–1079. [PubMed: 19328993]
3. Wilson DP. Data are lacking for quantifying HIV transmission risk in the presence of effective
antiretroviral therapy. AIDS. 2009; 23:1431–1433. [PubMed: 19487904]
4. Ruark A, Shelton JD, Halperin DT, et al. Universal voluntary HIV testing and immediate
antiretroviral therapy. Lancet. 2009; 373:1078. [PubMed: 19328994]
5. Cohen MS, Dye C, Fraser C, et al. HIV treatment as prevention: debate and Commentary—will
early infection compromise treatment-as-prevention strategies? PLoS Med. 2012; 9:e1001232.
[PubMed: 22802728]
6. Keele BF, Giorgi EE, Salazar-Gonzalez JF, et al. Identification and characterization of transmitted
and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci U S A. 2008;
105:7552–7557. [PubMed: 18490657]
7. Bar KJ, Li H, Chamberland A, et al. Wide variation in the multiplicity of HIV-1 infection among
injection drug users. J Virol. 2010; 84:6241–6247. [PubMed: 20375173]
8. Estes JD, Haase AT, Schacker TW. The role of collagen deposition in depleting CD4+ T cells and
limiting reconstitution in HIV-1 and SIV infections through damage to the secondary lymphoid
organ niche. Semin Immunol. 2008; 20:181–186. [PubMed: 18595731]
9. Cohen MS, Shaw GM, McMichael AJ, et al. Acute HIV-1 infection. N Engl J Med. 2011;
364:1943–1954. [PubMed: 21591946]
10. Borrow P, Hou S, Gloster S, et al. Virus infection-associated bone marrow B cell depletion and
impairment of humoral immunity to heterologous infection mediated by TNF-alpha/LTalpha. Eur
J Immunol. 2005; 35:524–532. [PubMed: 15657949]
11. Fiebig EW, Wright DJ, Rawal BD, et al. Dynamics of HIV viremia and antibody seroconversion in
plasma donors: implications for diagnosis and staging of primary HIV infection. AIDS. 2003;
17:1871–1879. [PubMed: 12960819]
12. Brenchley JM, Douek DC. The mucosal barrier and immune activation in HIV pathogenesis. Curr
Opin HIV AIDS. 2008; 3:356–361. [PubMed: 19372990]
13. Chun TW, Engel D, Berrey MM, et al. Early establishment of a pool of latently infected, resting
CD4(+) T cells during primary HIV-1 infection. Proc Natl Acad Sci U S A. 1998; 95:8869–8873.
[PubMed: 9671771]
14. McMichael AJ, Borrow P, Tomaras GD, et al. The immune response during acute HIV-1 infection:
clues for vaccine development. Nat Rev Immunol. 2010; 10:11–23. [PubMed: 20010788]
15. Ananworanich J, Schuetz A, Vandergeeten C, et al. Impact of multi-targeted antiretroviral
treatment on gut T cell depletion and HIV reservoir seeding during acute HIV infection. PLoS
One. 2012; 7:e33948. [PubMed: 22479485]
16. Brenner BG, Roger M, Routy JP, et al. High rates of forward transmission events after acute/early
HIV-1 infection. J Infect Dis. 2007; 195:951–959. [PubMed: 17330784]
Smith et al. Page 8






















17. Lavreys L, Baeten JM, Chohan V, et al. Higher set point plasma viral load and more-severe acute
HIV type 1 (HIV-1) illness predict mortality among high-risk HIV-1-infected African women.
Clin Infect Dis. 2006; 42:1333–1339. [PubMed: 16586394]
18. Ma ZM, Stone M, Piatak M, et al. High specific infectivity of plasma virus from the pre-ramp-up
and ramp-up stages of acute simian immunodeficiency virus infection. J Virol. 2009; 83:3288–
3297. [PubMed: 19129448]
19. Pilcher CD, Joaki G, Hoffman IF, et al. Amplified transmission of HIV-1: comparison of HIV-1
concentrations in semen and blood during acute and chronic infection. AIDS. 2007; 21:1723–
1730. [PubMed: 17690570]
20. Pilcher CD, Tien HC, Eron JJ, et al. Brief but efficient: acute HIV infection and the sexual
transmission of HIV. J Infect Dis. 2004; 189:1785–1792. [PubMed: 15122514]
21. Morrison CS, Demers K, Kwok C, et al. Plasma and cervical viral loads among Ugandan and
Zimbabwean women during acute and early HIV-1 infection. AIDS. 2010; 24:573–582. [PubMed:
20154581]
22. Pao D, Fisher M, Hué S, et al. Transmission of HIV-1 during primary infection: relationship to
sexual risk and sexually transmitted infections. AIDS. 2005; 19:85–90. [PubMed: 15627037]
23. Colfax GN, Buchbinder SP, Cornelisse PGA, et al. Sexual risk behaviors and implications for
secondary HIV transmission during and after HIV seroconversion. AIDS. 2002; 16:1529–1535.
[PubMed: 12131191]
24. Marks G, Crepaz N, Janssen RS. Estimating sexual transmission of HIV from persons aware and
unaware that they are infected with the virus in the USA. AIDS. 2006; 20:1447–1450. [PubMed:
16791020]
25. Powers KA, Ghani AC, Miller WC, et al. The role of acute and early HIV infection in the spread of
HIV and implications for transmission prevention strategies in Lilongwe, Malawi: a modelling
study. Lancet. 2011; 378:256–268. [PubMed: 21684591]
26. Lewis F, Hughes GJ, Rambaut A, et al. Episodic sexual transmission of HIV revealed by molecular
phylodynamics. PLoS Med. 2008; 5:e50. [PubMed: 18351795]
27. Yerly S, Vora S, Rizzardi P, et al. Acute HIV infection: impact on the spread of HIV and
transmission of drug resistance. AIDS. 2001; 15:2287–2292. [PubMed: 11698702]
28. Dennis AM, Hué S, Hurt CB, et al. Phylogenetic insights into regional HIV transmission. AIDS.
2012; 26:1813–1822. [PubMed: 22739398]
29. Fisher M, Pao D, Brown AE, et al. Determinants of HIV-1 transmission in men who have sex with
men: a combined clinical, epidemiological and phylogenetic approach. AIDS. 2010; 24:1739–
1747. [PubMed: 20588173]
30. Brown AE, Gifford RJ, Clewley JP, et al. Phylogenetic reconstruction of transmission events from
individuals with acute HIV infection: toward more-rigorous epidemiological definitions. J Infect
Dis. 2009; 199:427–431. [PubMed: 19133810]
31. Miller WC, Rosenberg NE, Rutstein SE, et al. Role of acute and early HIV infection in the sexual
transmission of HIV. Curr Opin HIV AIDS. 2010; 5:277–282. [PubMed: 20543601]
32. Jacquez JA, Koopman JS, Simon CP, et al. Role of the primary infection in epidemics of HIV
infection in gay cohorts. J Acquir Immune Defic Syndr. 1994; 7:1169–1184. [PubMed: 7932084]
33. Pinkerton SD, Abramson PR. Implications of increased infectivity in early-stage HIV infection
application of a Bernoulli-process model of HIV transmission. Eval Rev. 1996; 20:516–540.
[PubMed: 10183259]
34. Koopman JS, Jacquez JA, Welch GW, et al. The role of early HIV infection in the spread of HIV
through populations. J Acquir Immune Defic Syndr Hum Retrovirol. 1997; 14:249–258. [PubMed:
9117458]
35. Kretzschmar M, Dietz K. The effect of pair formation and variable infectivity on the spread of an
infection without recovery. Math Biosci. 1998; 148:83–113. [PubMed: 9597826]
36. Coutinho FA, Lopez LF, Burattini MN, et al. Modelling the natural history of HIV infection in
individuals and its epidemiological implications. Bull Math Biol. 2001; 63:1041–1062. [PubMed:
11732175]
Smith et al. Page 9






















37. Xiridou M, Geskus R, De Wit J, et al. Primary HIV infection as source of HIV transmission within
steady and casual partnerships among homosexual men. AIDS. 2004; 18:1311–1320. [PubMed:
15362664]
38. Pinkerton SD. How many sexually-acquired HIV infections in the USA are due to acute-phase
HIV transmission? AIDS. 2007; 21:1625–1629. [PubMed: 17630558]
39. Prabhu VS, Hutchinson AB, Farnham PG, et al. Sexually acquired HIV infections in the United
States due to acute-phase HIV transmission: an update. AIDS. 2009; 23:1792–1794. [PubMed:
19684485]
40. Goodreau SM, Cassels S, Kasprzyk D, et al. Concurrent partnerships, acute infection and HIV
epidemic dynamics among young adults in Zimbabwe. AIDS Behav. 2012; 16:312–322. [PubMed:
21190074]
41. Hayes RJ, White RG. Amplified HIV transmission during early-stage infection. J Infect Dis. 2006;
193:604–605. author reply 605–606. [PubMed: 16425144]
42. Eaton JW, Hallett TB, Garnett GP. Concurrent sexual partnerships and primary HIV infection: a
critical interaction. AIDS Behav. 2011; 15:687–692. [PubMed: 20890654]
43. Pinkerton SD. Probability of HIV transmission during acute infection in Rakai, Uganda. AIDS
Behav. 2008; 12:677–684. [PubMed: 18064559]
44. Abu-Raddad LJ, Longini IM. No HIV stage is dominant in driving the HIV epidemic in sub-
Saharan Africa. AIDS. 2008; 22:1055–1061. [PubMed: 18520349]
45. Salomon JA, Hogan DR. Evaluating the impact of antiretroviral therapy on HIV transmission.
AIDS. 2008; 22(suppl 1):S149–S159. [PubMed: 18664947]
46. Hollingsworth TD, Anderson RM, Fraser C. HIV-1 transmission, by stage of infection. J Infect
Dis. 2008; 198:687–693. [PubMed: 18662132]
47. Napierala-Mavedzenge S, Gaydos CA, Makombe SD. The uptake and accuracy of oral kits for
HIV self-testing in high HIV prevalence setting: a cross-sectional feasibility study in Blantyre,
Malawi. PLoS Med. 2011; 8:e1001102. [PubMed: 21990966]
48. Zetola NM, Pilcher CD. Diagnosis and management of acute HIV infection. Infect Dis Clin North
Am. 2007; 21:19–48. vii. [PubMed: 17502228]
49. Patel P, Mackellar D, Simmons P, et al. Detecting acute human immunodeficiency virus infection
using 3 different screening immunoassays and nucleic acid amplification testing for human
immunodeficiency virus RNA, 2006–2008. Arch Intern Med. 2010; 170:66–74. [PubMed:
20065201]
50. Stekler JD, Swenson PD, Coombs RW, et al. HIV testing in a high-incidence population: is
antibody testing alone good enough? Clin Infect Dis. 2009; 49:444–453. [PubMed: 19538088]
51. Eshleman SH, Khaki L, Laeyendecker O, et al. Detection of individuals with acute HIV-1 infection
using the ARCHITECT HIV Ag/Ab Combo assay. J Acquir Immune Defic Syndr. 2009; 52:121–
124. [PubMed: 19506484]
52. Chetty V, Moodley D, Chuturgoon A. Evaluation of a 4th generation rapid HIV test for earlier and
reliable detection of HIV infection in pregnancy. J Clin Virol. 2012; 54:180–184. [PubMed:
22445263]
53. Karris MY, Anderson CM, Morris SR, et al. Cost savings associated with testing of antibodies,
antigens, and nucleic acids for diagnosis of acute HIV infection. J Clin Microbiol. 2012; 50:1874–
1878. [PubMed: 22442319]
54. Quinn TC, Brookmeyer R, Kline R, et al. Feasibility of pooling sera for HIV-1 viral RNA to
diagnose acute primary HIV-1 infection and estimate HIV incidence. AIDS. 2000; 14:2751–2757.
[PubMed: 11125894]
55. Fiscus SA, Pilcher CD, Miller WC, et al. Rapid, real-time detection of acute HIV infection in
patients in Africa. J Infect Dis. 2007; 195:416–424. [PubMed: 17205481]
56. Westreich DJ, Hudgens MG, Fiscus SA, et al. Optimizing screening for acute human
immunodeficiency virus infection with pooled nucleic acid amplification tests. J Clin Microbiol.
2008; 46:1785–1792. [PubMed: 18353930]
57. Kerndt PR, Dubrow R, Aynalem G, et al. Strategies used in the detection of acute/early HIV
infections. The NIMH Multisite Acute HIV Infection Study: I. AIDS Behav. 2009; 13:1037–1045.
[PubMed: 19495954]
Smith et al. Page 10






















58. Hutchinson AB, Patel P, Sansom SL, et al. Cost-effectiveness of pooled nucleic acid amplification
testing for acute HIV infection after third-generation HIV antibody screening and rapid testing in
the United States: a comparison of three public health settings. PLoS Med. 2010; 7:e1000342.
[PubMed: 20927354]
59. Rosenberg NE, Kamanga G, Phiri S, et al. Detection of acute HIV infection: a field evaluation of
the determine® HIV-1/2 Ag/Ab combo test. J Infect Dis. 2012; 205:528–534. [PubMed:
22207651]
60. Pavie J, Rachline A, Loze B, et al. Sensitivity of five rapid HIV tests on oral fluid or finger-stick
whole blood: a real-time comparison in a health-care setting. PLoS One. 2010; 5:e11581.
[PubMed: 20657834]
61. Powers KA, Poole C, Pettifor AE, et al. Rethinking the heterosexual infectivity of HIV-1: a
systematic review and meta-analysis. Lancet Infect Dis. 2008; 8:553–563. [PubMed: 18684670]
62. Miller WC, Leone PA, McCoy S, et al. Targeted testing for acute HIV infection in North Carolina.
AIDS. 2009; 23:835–843. [PubMed: 19318909]
63. Gazzard BG, Anderson J, Babiker A, et al. British HIV Association Guidelines for the treatment of
HIV-1-infected adults with antiretroviral therapy 2008. HIV Med. 2008; 9:563–608. [PubMed:
18826546]
64. Steward WT, Remien RH, Higgins JA, et al. Behavior change following diagnosis with acute/early
HIV infection—a move to serosorting with other HIV-infected individuals. The NIMH Multisite
Acute HIV Infection Study: III. AIDS Behav. 2009; 13:1054–1060. [PubMed: 19504178]
65. Pettifor A, MacPhail C, Corneli A, et al. Continued high risk sexual behavior following diagnosis
with acute HIV infection in South Africa and Malawi: implications for prevention. AIDS Behav.
2011; 15:1243–1250. [PubMed: 20978833]
66. Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human
immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med. 2000; 342:921–929.
[PubMed: 10738050]
67. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral
therapy. N Engl J Med. 2011; 365:493–505. [PubMed: 21767103]
68. Rieder P, Joos B, von Wyl V, et al. HIV-1 transmission after cessation of early antiretroviral
therapy among men having sex with men. AIDS. 2010; 24:1177–1183. [PubMed: 20386427]
69. El-Sadr WM, Lundgren JD, et al. Strategies for Management of Antiretroviral Therapy (SMART)
Study Group. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med. 2006;
355:2283–2296. [PubMed: 17135583]
70. Harrington M, Carpenter CC. Hit HIV-1 hard, but only when necessary. Lancet. 2000; 355:2147–
2152. [PubMed: 10902643]
71. Archin NM, Vaidya NK, Kuruc JD, et al. Immediate antiviral therapy appears to restrict resting
CD4+ cell HIV-1 infection without accelerating the decay of latent infection. Proc Natl Acad Sci
U S A. 2012; 109:9523–9528. [PubMed: 22645358]
72. Bacchus, C.; Hocqueloux, L.; Avettand-Fenoel, V., et al. Distribution of the HIV reservoir in
patients spontaneously controlling HIV infection after treatment interruption. Presented Mar 5–8,
2012 at the 19th International AIDS Conference; Seattle, WA.
73. Cellerai C, Harari A, Stauss H, et al. Early and prolonged antiretroviral therapy is associated with
an HIV-1-specific T-cell profile comparable to that of long-term non-progressors. PLoS One.
2011; 6:e18164. [PubMed: 21483676]
74. Desquilbet L, Goujard C, Rouzioux C, et al. Does transient HAART during primary HIV-1
infection lower the virological set-point? AIDS. 2004; 18:2361–2369. [PubMed: 15622312]
75. Evering TH, Mehandru S, Racz P, et al. Absence of HIV-1 evolution in the gut-associated
lymphoid tissue from patients on combination antiviral therapy initiated during primary infection.
PLoS Pathog. 2012; 8:e1002506. [PubMed: 22319447]
76. Fidler S, Fraser C, Fox J, et al. Comparative potency of three antiretroviral therapy regimes in
primary HIV infection. AIDS. 2006; 20:247–252. [PubMed: 16511418]
77. Fidler S, Fox J, Touloumi G, et al. Slower CD4 cell decline following cessation of a 3 month
course of HAART in primary HIV infection: findings from an observational cohort. AIDS. 2007;
21:1283–1291. [PubMed: 17545704]
Smith et al. Page 11






















78. Gay C, Dibben O, Anderson JA, et al. Cross-sectional detection of acute HIV infection: timing of
transmission, inflammation and antiretroviral therapy. PLoS One. 2011; 6:e19617. [PubMed:
21573003]
79. Gianella S, von Wyl V, Fischer M, et al. Effect of early antiretroviral therapy during primary
HIV-1 infection on cell-associated HIV-1 DNA and plasma HIV-1 RNA. Antivir Ther. 2011;
16:535–545. [PubMed: 21685541]
80. Goujard C, Emilie D, Roussillon C, et al. Continuous versus intermittent treatment strategies
during primary HIV-1 infection: the randomized ANRS INTERPRIM Trial. AIDS. 2012;
26:1895–1905. [PubMed: 22842994]
81. Goujard C, Girault I, Rouzioux C, et al. HIV-1 control after transient antiretroviral treatment
initiated in primary infection: role of patient characteristics and effect of therapy. Antivir Ther.
2012; 17:1001–1009. [PubMed: 22865544]
82. Grijsen ML, Koster GT, van Vonderen M, et al. Temporary antiretroviral treatment during primary
HIV-1 infection has a positive impact on health-related quality of life: data from the Primo-SHM
cohort study. HIV Med. 2012; 13:630–635. [PubMed: 22533544]
83. Grijsen ML, Steingrover R, Wit FW, et al. No treatment versus 24 or 60 weeks of antiretroviral
treatment during primary HIV infection: the randomized Primo-SHM trial. PLoS Med. 2012;
9:e1001196. [PubMed: 22479156]
84. Hecht FM, Wang L, Collier A, et al. A multicenter observational study of the potential benefits of
initiating combination antiretroviral therapy during acute HIV infection. J Infect Dis. 2006;
194:725–733. [PubMed: 16941337]
85. Hocqueloux L, Prazuck T, Avettand-Fenoel V, et al. Long-term immunovirologic control
following antiretroviral therapy interruption in patients treated at the time of primary HIV-1
infection. AIDS. 2010; 24:1598–1601. [PubMed: 20549847]
86. Hoen B, Cooper DA, Lampe FC, et al. Predictors of virological outcome and safety in primary
HIV type 1-infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005.
Clin Infect Dis. 2007; 45:381–390. [PubMed: 17599319]
87. Hogan CM, Degruttola V, Sun X, et al. The setpoint study (ACTG A5217): effect of immediate
versus deferred antiretroviral therapy on virologic set point in recently HIV-1-infected individuals.
J Infect Dis. 2012; 205:87–96. [PubMed: 22180621]
88. Jain, V.; Hartogensis, W.; Bacchetti, P., et al. ART initiation during acute/early HIV infection
compared to later ART initiation with improved immunologic and virologic parameters during
suppressive ART. Presented Feb 27 – Mar 2, 2011 at the 18th Conference on Retroviruses and
Opportunistic Infections; Boston, MA.
89. Jansen CA, De Cuyper IM, Steingrover R, Jurriaans S, Sankatsing SU, Prins JM, et al. Analysis of
the effect of highly active antiretroviral therapy during acute HIV-1 infection on HIV-specific
CD4 T cell functions. AIDS. 2005; 19:1145–1154. [PubMed: 15990567]
90. Kaufmann DE, Lichterfeld M, Altfeld M, et al. Limited durability of viral control following treated
acute HIV infection. PLoS Med. 2004; 1:e36. [PubMed: 15526059]
91. Kinloch-De Loes S, Hirschel BJ, Hoen B, et al. A controlled trial of zidovudine in primary human
immunodeficiency virus infection. N Engl J Med. 1995; 333:408–413. [PubMed: 7616989]
92. Koegl C, Wolf E, Hanhoff N, et al. Treatment during primary HIV infection does not lower viral
set point but improves CD4 lymphocytes in an observational cohort. Eur J Med Res. 2009;
14:277–283. [PubMed: 19661009]
93. Lampe FC, Porter K, Kaldor J, et al. Effect of transient antiretroviral treatment during acute HIV
infection: comparison of the Quest trial results with CASCADE natural history study. Antivir
Ther. 2007; 12:189–193. [PubMed: 17503661]
94. Le T, Wright EJ, Smith DM, et al. Enhanced CD4+ T-cell recovery with earlier HIV-1
antiretroviral therapy. N Engl J Med. 2013; 368:218–230. [PubMed: 23323898]
95. Lodi S, Meyer L, Kelleher AD, et al. Immunovirologic control 24 months after interruption of
antiretroviral therapy initiated close to HIV seroconversion. Arch Intern Med. 2012; 172:1252–
1255. [PubMed: 22826124]
Smith et al. Page 12






















96. Markowitz M, Jin X, Hurley A, et al. Discontinuation of antiretroviral therapy commenced early
during the course of human immunodeficiency virus type 1 infection, with or without adjunctive
vaccination. J Infect Dis. 2002; 186:634–643. [PubMed: 12195350]
97. Mehandru S, Poles MA, Tenner-Racz K, et al. Lack of mucosal immune reconstitution during
prolonged treatment of acute and early HIV-1 infection. PLoS Med. 2006; 3:e484. [PubMed:
17147468]
98. Moir S, Buckner CM, Ho J, et al. B cells in early and chronic HIV infection: evidence for
preservation of immune function associated with early initiation of antiretroviral therapy. Blood.
2010; 116:5571–5579. [PubMed: 20837780]
99. Niu MT, Bethel J, Holodniy M, et al. Zidovudine treatment in patients with primary (acute) human
immunodeficiency virus type 1 infection: a randomized, double-blind, placebo-controlled trial.
DATRI 002 Study Group. Division of AIDS Treatment Research Initiative. J Infect Dis. 1998;
178:80–91. [PubMed: 9652426]
100. Oxenius A, Price DA, Easterbrook PJ, O’Callaghan CA, Kelleher AD, Whelan JA, et al. Early
highly active antiretroviral therapy for acute HIV-1 infection preserves immune function of
CD8+ and CD4+ T lymphocytes. Proc Natl Acad Sci U S A. 2000; 97:3382–3387. [PubMed:
10737796]
101. Pantazis N, Touloumi G, Vanhems P, et al. The effect of antiretroviral treatment of different
durations in primary HIV infection. AIDS. 2008; 22:2441–2450. [PubMed: 19005267]
102. Prazuck, T.; Lafeuillade, A.; Hocqueloux, L., et al. Can HAART at early acute HIV infection
benefit the immune-virology outcome despite subsequent treatment cessation?. Presented Feb 3–
6, 2008 at the 15th Conference on Retroviruses and Opportunistic Infections; 2008; Boston, MA..
103. Rosenberg ES, Altfeld M, Poon SH, et al. Immune control of HIV-1 after early treatment of acute
infection. Nature. 2000; 407:523–526. [PubMed: 11029005]
104. Rosenberg ES, Graham BS, Chan ES, et al. Safety and immunogenicity of therapeutic DNA
vaccination in individuals treated with antiretroviral therapy during acute/early HIV-1 infection.
PLoS One. 2010; 5:e10555. [PubMed: 20479938]
105. Sáez-Cirión A, Bacchus C, Hocqueloux L, et al. Post-treatment HIV-1 controllers with a long-
term virological remission after the interruption of early initiated antiretroviral therapy ANRS
VISCONTI Study. PLoS Pathog. 2013; 9:e1003211. [PubMed: 23516360]
106. Seng R, Goujard C, Desquilbet L, et al. Rapid CD4+ cell decrease after transient cART initiated
during primary HIV infection (ANRS PRIMO and SEROCO cohorts). J Acquir Immune Defic
Syndr. 2008; 49:251–258. [PubMed: 18845951]
107. SPARTAC Trial Investigators. Short-course antiretroviral therapy in primary HIV infection. N
Engl J Med. 2013; 368:1–11. [PubMed: 23234473]
108. Steingrover R, Pogany K, Fernandez Garcia E, et al. HIV-1 viral rebound dynamics after a single
treatment interruption depends on time of initiation of highly active antiretroviral therapy. AIDS.
2008; 22:1583–1588. [PubMed: 18670217]
109. Steingrover R, Garcia EF, van Valkengoed IG, et al. Transient lowering of the viral set point after
temporary antiretroviral therapy of primary HIV type 1 infection. AIDS Res Hum Retroviruses.
2010; 26:379–387. [PubMed: 20377419]
110. Streeck H, Jessen H, Alter G, et al. Immunological and virological impact of highly active
antiretroviral therapy initiated during acute HIV-1 infection. J Infect Dis. 2006; 194:734–739.
[PubMed: 16941338]
111. Tilling R, Kinloch S, Goh L-E, et al. Parallel decline of CD8+/CD38++ T cells and viraemia in
response to quadruple highly active antiretroviral therapy in primary HIV infection. AIDS. 2002;
16:589–596. [PubMed: 11873002]
112. Vinikoor MJ, Cope A, Gay CL, et al. Antiretroviral therapy initiated during acute HIV infection
fails to prevent persistent T cell activation. J Acquir Immune Defic Syndr. 2013 Epub ahead of
print.
113. Volberding P, Demeter L, Bosch RJ, et al. Antiretroviral therapy in acute and recent HIV
infection: a prospective multicenter stratified trial of intentionally interrupted treatment. AIDS.
2009; 23:1987–1995. [PubMed: 19696651]
Smith et al. Page 13






















114. Wyl V, Gianella S, Fischer M, et al. Early antiretroviral therapy during primary HIV-1 infection
results in a transient reduction of the viral setpoint upon treatment interruption. PLoS One. 2011;
6:e27463. [PubMed: 22102898]
115. Younes SA, Trautmann L, Yassine-Diab B, et al. The duration of exposure to HIV modulates the
breadth and the magnitude of HIV-specific memory CD4 T cells. J Immunol. 2007; 178:788–
797. [PubMed: 17202340]
116. Clark SJ, Shaw GM. The acute retroviral syndrome and the pathogenesis of HIV-1 infection.
Semin Immunol. 1993; 5:149–155. [PubMed: 8347840]
117. Kahn JO, Walker BD. Acute human immunodeficiency virus type 1 infection. N Engl J Med.
1998; 339:33–39. [PubMed: 9647878]
118. McKellar MS, Cope AB, Gay CL, et al. Acute HIV-1 infection in the Southeastern United States:
a cohort study. AIDS Res Hum Retroviruses. 2013; 29:121–128. [PubMed: 22839749]
119. Socías ME, Sued O, Laufer N, et al. Acute retroviral syndrome and high baseline viral load are
predictors of rapid HIV progression among untreated Argentinean seroconverters. J Int AIDS
Soc. 2011; 14:40. [PubMed: 21831310]
120. Henard S, Jeanmaire E, Nguyen Y, et al. Is total community viral load a robust predictive marker
of the efficacy of the TasP strategy? J Acquir Immune Defic Syndr. 2012; 61:400–402. [PubMed:
22732466]
121. Chun TW, Fauci AS. HIV reservoirs: pathogenesis and obstacles to viral eradication and cure.
AIDS. 2012; 26:1261–1268. [PubMed: 22472858]
122. Pierson T, McArthur J, Siliciano RF. Reservoirs for HIV-1: mechanisms for viral persistence in
the presence of antiviral immune responses and antiretroviral therapy. Annu Rev Immunol. 2000;
18:665–708. [PubMed: 10837072]
123. Pires A, Hardy G, Gazzard B, et al. Initiation of antiretroviral therapy during recent HIV-1
infection results in lower residual viral reservoirs. J Acquir Immune Defic Syndr. 2004; 36:783–
790. [PubMed: 15213561]
124. Buzon, M.; Mclaren, P.; Seiss, K., et al. Reduced HIV-1 reservoir size after 10 years of
suppressive antiretroviral therapy in patients initiating treatment during primary infection.
Presented Dec 6–9, 2011 at the Fifth International Workshop on HIV Persistence During
Therapy; 2011; St Maarten, The Netherlands..
125. Saez-Cirion, A.; Hocqueloux, L.; Avettand-Fenoel, V., et al. Long-term HIV-1 control after
interruption of treatment initiated at the time of primary infection is associated to low cell-
associated HIV DNA levels: ANRS VISCONTI Study. Presented Feb 27 – Mar 2, 2011 at the
18th Conference on Retroviruses and Opportunistic Infections; Boston, MA..
126. Hütter G, Nowak D, Mossner M, et al. Long-term control of HIV by CCR5 Delta32/Delta32
stem-cell transplantation. N Engl J Med. 2009; 360:692–698. [PubMed: 19213682]
127. Persaud, D.; Gay, H.; Ziemniak, C., et al. Functional HIV cure after very early ART of an
infected infant. Presented Mar 3–6, 2013 at the 20th Conference on Retroviruses and
Opportunistic Infections; Atlanta, GA..
128. Rebeiro P, Althoff KN, Buchacz K, et al. Retention among North American HIV-infected persons
in clinical care, 2000–2008. J Acquir Immune Defic Syndr. 2012 Epub ahead of print.
129. University of Minnesota Clinical and Translational Science Institute. START - Strategic timing of
Antiretroviral treatment. University of Minnesota Clinical and Translational Science Institute;
Available at: http://insight.ccbr.umn.edu/start/ [Accessed April 18 2013]
130. World Health Organization. Antiretroviral Therapy for HIV Infection in Adults and Adolescents.
2011. p. 1-156.
131. Department of Health and Human Services. [Accessed February 12, 2013] Panel on Antiretroviral
Guidelines for Adults and Adolescents. Guidelines for the use of anti-retroviral agents in HIV-1-
infected adults and adolescents. Available at: http://aidsinfo.nih.gov/guidelines
132. Thompson MA, Aberg JA, Cahn P, et al. Antiretroviral treatment of adult HIV infection: 2010
recommendations of the International AIDS Society-USA panel. JAMA. 2010; 304:321–333.
[PubMed: 20639566]
Smith et al. Page 14











































Smith et al. Page 15
TABLE 1
Evidence to Date on the Feasibility of Treatment as Prevention Targeting Persons With EHI
Things for Which There Is Some Evidence Unknowns
ART at CD4 > 350 cells/mL reduces infectiousness by
96% in stable serodiscordant couples
How well ART can reduce infectiousness in persons with EHI, particularly in the
preseroconversion phase
The extent to which EHI may contribute to ongoing
transmission
How likely we are to be able to identify and treat a large enough portion of EHI
to impact the efficacy of treatment as prevention within a population
Early ART can suppress viral load in individuals with EHI The long-term safety of early ART, and the durability of the suppressive effect
Some regimens may be more effective at reducing viral
load
The tolerability (toxicity) and the long-term safety of these regimens, although
this may not be significantly different from those affecting the general
population starting ART in chronic infection
Early ART has some short-term health benefits for the
individual
Long-term health benefits of early ART for the individual
Adherence to short course is generally good Feasibility of good adherence in the event of uninterrupted therapy
Resource poor areas have limited capacity to screen acutes
or to provide routine viral load testing
The extent to which new technologies will be able to overcome these constraints
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TABLE 2
Proportion of New Infection Attributed to Early EHI
Author Population/Setting Proportion of New Infections Attributed to EHI (%)
Jacquez et al32 MSM (United States) 25 to 51
Pinkerton and Abramson33 MSM (United States) 25 to 90*
Koopman et al34 MSM (United States) 20 to 47*
Kretzschmar and Dietz35 Hypothetical (United States) 65 to 82*‡
Coutinho et al36 Mixed 2 to 89
Xiridou et al37 MSM (Europe) <1 to 39
Pinkerton38 Mixed (United States) 3 to 17
Prabhu et al39 Mixed (United States) 11
Goodreau et al40 Heterosexuals (SSA) 20 to 25
Hayes and White41 Heterosexuals (SSA) 23 to 41†
Eaton et al42 Heterosexuals (SSA) 16 to 28*
Pinkerton43 Heterosexuals (SSA) 85 to 93†
Abu-Raddad and Longini44 Heterosexuals (SSA) ~7 to ~15‡
Salomon and Hogan45 Heterosexuals (SSA) ~20 to 40†
Hollingsworth et al46 Heterosexuals (SSA) 9 to 31
Powers et al25 Heterosexuals (SSA) 19 to 52‡
MSM, men who have sex with men; SSA, sub-Saharan Africa.
*
Transmission probabilities were drawn from the listed population, but the reported proportion of new infections attributed to EHI result from a
range of hypothetical sexual behavior parameters that do not necessarily reflect those of the same subpopulation.
†
Range of estimates reflect the estimated proportion of transmissions during an HIV infected person’s entire infectious period that occur during
EHI. The extent to which this proportion corresponds with the proportion of all transmissions that occur during EHI at the population level will
depend on the epidemic phase and sexual contact patterns.
‡
The range of estimates shown was extracted from the endemic-phase portion of graphs showing the time-course of the proportion due to EHI.
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TABLE 3
Summary of Studies of the Virological or Immunological Effects of ART Administered During EHI (≤6
Months After Seroconversion)
Author Setting Cohort Name/Study Design N Comparator Group
Ananworanich et al15 Asia Open-label treatment 2-arm trial 30 15 HIV+ ART naive
Archin et al71 NA CHAVI/STAT 27 —
Bacchus et al72 ER VISCOTI 12 (all control HIV
after interruption)
—
Cellerai et al73 ER Retrospective clinical 20 15 HIV+ ART naive
long-term nonprogressors
Desquilbet et al74 ER PRIMO (SERECO controls) 58 116 HIV+ ART naive
Evering et al75 NA Clinical 3 2
Fidler et al76 ER Clinical 79 —
Fidler et al77 ER Clinical (CASCADE controls) 89 179 HIV+ ART naive
Gay et al78 NA UNC Duke Acute HIV Infection
Consortium
51 92 HIV+ ART naive
Gianella et al79 ER Clinical (Swiss HIV Cohort
Study controls)
32 89 HIV+ ART naive with
recent EDI
Goujard et al80 ER RCT: ANRS-112 INTERPRIM
3-arm Trial




Goujard et al81 ER ANRS PRIMO 164 —
Grijsen et al82 ER PRIMO-SHM substudy 84 28 HIV+ ART naive
Grijsen et al83 ER RCT: PRIMO-SHM 3-arm trial 38: 24 wk cART 38:
60 wk cART
36: no (deferred) ART
Hecht et al84 NA AIEDRP cohort 13 acute 45 early 337 HIV+ ART naive
Hocquelox et al85 ER Retrospective clinical 32 —
Hoen et al86 ER, NA QUEST GW 148 —
Hogan et al87 NA RCT: ACTG 5217 (set point) 66 63: no (deferred) ART
Jain et al88 NA UCSF Options Project 32 34 HIV+, ART initiated
later (unknown N of HIV
− controls)
Jansen et al89 ER Clinical 11 6 HIV+ ART naive
Kaufman et al90 NA Single-arm open-label 14 —
Kinloch-de Loes et al and Koegl
et al91,92
ER RCT 39 38: placebo
Koegl et al92 ER Clinical AHI/PHI cohorts 100 56 HIV+ ART naive
Lampe et al93 ER QUEST (CASCADE controls) 79 358 HIV+ ART naive
Le et al94 NA San Diego Primary Infection
Cohort
213 136 HIV+ ART naive
Lodi et al95 ER, NA, AUS CASCADE m —
Markowitz et al96 NA Clinical 16 (11 of whom also
part of a vaccine trial)
—
Mehandru et al97 NA Clinical 54 18 uninfected controls
Moir et al98 NA Clinical 43: early 50:chronic 35 HIV−
Niu et al99 NA RCT: DAIDS Treatment
Initiative
13 15: placebo
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Author Setting Cohort Name/Study Design N Comparator Group
Oxenius et al100 ER Clinical 8 —
Pantazis et al101 ER, NA, AUS CASCADE 1023 —
Prazuck et al102 ER Clinical 20 18 HIV+ ART naive
Reider et al68 ER Zurich Primary HIV cohort and
Swiss HIV Cohort Study
111 —
Rosenberg et al103 NA Clinical 18 6 AHI ART naive
Rosenberg et al104 NA RCT: ACTG A5187 Study 20 —
Saez-Cirion et al105 ER VISCONTI 14 Untreated HIV
controllers, viremics, and
treated chronics
Seng et al106 ER ANRS PRIMO and SEROCO 293 —
SPARTAC Trial Investigators107 Multicountry RCT: SPARTAC Trial 120: 12 wk ART 118:
48 wk ART
124 standard of care (no
ART)
Steingrover et al108 ER Clinical (TRIESTAN study
controls)
26 46 HIV+ controls;
initiated ART during
chronic infection
Steingrover et al109 ER Dutch HIV Monitoring
Foundation Cohort/Amsterdam
Cohort Studies
32 250 HIV+ late ART
initiators
Stekler et al50 NA Seattle Primary Infection Cohort
(historical controls)
157 27 historical + 60
contemporary controls
Streeck et al110 ER Clinical 12 8
Tilling et al111 ER, AUS Quest Study — —
Vinikoor et al112 NA Open-label treatment trial 31 30 HIV− controls
Volberding et al113 NA ACTG 371 single-arm trial 28 45 “recent” HIV
infections (versus acute)
Wyl et al114 ER Zurich Primary HIV cohort
(Swiss HIV Cohort Study
controls)
33 79 chronic HIV, ART
naive






RI Immunological Outcomes Virological Outcomes
Ananworanich et al15 3 arms of elective ART: 5
class “megaHAART” versus
3 class regimen initiated
within 3 d of enrollment for
24 wk
AHI: M CD4+CCR5+ gut T cells
increased from 41% at
baseline to 64% at 24 wk
<50 copies achieved in
14/15 patients in blood
and 13/13 in gut. Total
blood HIV DNA at 0 wk
predicted reservoir size
at 24 wk
Archin et al71 ART within 45 d of EDI AHI: B and
F
Degree of resting cell
infection is directly related to
the availability of CD4+ T
cells susceptible to HIV,
regardless of whether viremia
is controlled by the immune
response and/or ART
Success of early ART
may depend to a certain
extent on whether or not
infected resting CD4+ T
cells are stable
Bacchus et al72 ART initiated 10 wk
postinfection for 3 yrs
— — HIV DNA reservoir
distributed large in short-
lived memory CD4+ T
cells




Early ART results in levels of
highly polyfunctional HIV-1–
specific CD4+ and CD8+ T
—




























RI Immunological Outcomes Virological Outcomes
(C and/or
F)
cells as in long-term
nonprogressors




— No difference in viral set






Evering et al75 ART started within 72 h of
flexible sigmoidoscopy
AHI: M ART may halt measurable
evolution of HIV-1 quasi-
species derived from the
gastrointestinal tract; meaning
immune activation in the gut
may persist whether or not
there is viral replication
—
Fidler et al76 3 arms of elective short
course: 4 drug, 3 drug, PI
only
AHI: G or F
or (A and
B) or L
No differences in rate of CD4
recovery by arm
Faster VL decline in
patients on 4 drug
regimen compared with
3 drug or PI-containing
ART
Fidler et al77 Elective 3 mth short course at
PHI
PHI: E or F
or L
Rate of CD4 decline slower in
treated group over 3 yrs
No difference in mean
VL at 2 yrs
Gay et al78 NNRTI-based 3 drug




baseline activation level of
CD8+CD38+HLA-DR+ T
cells
More rapid viral decline
in treated AHI patients
than controls
Gianella et al79 Elective standard 1st line
within 120 d of EDI; option





RI: I or (B
and J) and
(F or I) or
K
— Early ART associated
with lower plasma and
cell RNA as compared
with late starters and
ART naive for >1 yr
after ART cessation
Goujard et al80 ART = continuous therapy;
ART-STI = 36 wk ART with
three 4 wk interruptions;






CD4+ T-cell counts and
CD4+/CD8+ T cell ratios
similar between groups after








87% of the patients
achieved undetectable
RNA at 32 wk; but RNA
and HIV DNA levels
were same after 6 mth
interruption
Goujard et al81 Standard therapy according
to national guidelines within
3 mth of EDI who interrupted




Controllers had lower levels
of specific CD8+ T-cell





Grijsen et al82 Forty-five 24 wk SCART;
thirty-nine 60 wk SCART;






Grijsen et al83 3 class regimen for 24 or 60






Time to reinitiation of therapy
longer in both ART arms
ART lowered viral set
point (plasma VL at 36
wk after interruption)
Hecht et al84 Elective ART for ≥12 wk





or E or (A
and F)
CD4+ T-cell counts higher in
early group at 24 and 72 wk
Differences in RNA
levels across groups at
24 wk gone by 72 wk




























RI Immunological Outcomes Virological Outcomes
Hocquelox et al85 ART within 3 mo of PHI,




Controllers had more stable
CD4+ counts over time
5/32 controlled VL for
med 6.25 yrs




Median increase in CD4+ 147
cells/mL by 48 wk
Median decrease in VL

















Delayed ART group had





DNA. % of activated
CD4+ and CD8+ T cells
associated with size of
reservoir
Jansen et al89 Intensive 5-class regimen




ART associated with more
HIV- specific CD4+ T cells
but this wasn’t associated





VL up to 2 yrs later.






EHI: G or F
Gradual decrease in CD4+
and viremia levels over time
after interruption; baseline
HIV-specific immune
activation did not predict
duration of viral control
Kinloch-de Loes et al and Koegl
et al91,92




CD4 cell counts differed
across arms by 6 mth
—
Koegl et al92 3 or 4 class regimen as
determined by physician,





increase in CD4 count;
untreated group CD4 fell.
Time to CD4 < 3350
significantly shorter in
untreated group
Med VL in ART group
lower 6 mth post
cessation, difference
gone by 12 mth
Lampe et al93 3 or 4 class regimen as part







prevalence at 3 yrs
higher in untreated, but
effect of transient ART
on long-term VL is
likely modest
Le et al94 97 initiated within 4 mth
post-EDI; 116 initiated after
4 mth EDI
PHI: K Earlier ART initiation was
associated with larger portion
of and faster pace of CD4+ T-
cell recovery
No association between
VL at ART initiation and
CD4+ T-cell recovery
Lodi et al95 ART initiated within 3 mth





within median 1.7 mth
after treatment
interruption
Markowitz et al96 ART initiated during EHI;
voluntarily discontinued after
mean 3.2 yrs




rebound present in all
subjects after mean 26 d,
followed by a significant
but transient (mean 1 yr)
suppression in all but 1
subject




























RI Immunological Outcomes Virological Outcomes
Mehandru et al97 ART initiated during acute/
early infection. Range 1–7
yrs of ART
AHI: M ART during AHI/EHI does
not lead to complete immune











Early ART associated with
better B-cell function
recovery against HIV and
non-HIV antigens
—
Niu et al99 Daily high-dose zidovudine AHI: (H
and A and
B) or K
Significantly higher CD4 in
treated subjects after 6 mth of
therapy
No difference across 2
arms in plasma VL after
6 mth
Oxenius et al100 3 class regimen initiated




ART during PHI preserves
HIV-specific CD4+ and CD8+
T cell physically and
functionally (HIV-specific
immunity), even when ART
is intermittent
—
Pantazis et al101 Early (N = 675) treated
within 6 mth of
seroconversion for ≥30 d;





CD4 cells lost rapidly after
cessation but subsequent loss
rate equal to untreated
No difference in VL set
points, defined as mean
of all available VL
measures post-ART
Prazuck et al102 Elective ART initiated within
10 wk of symptomatic AHI;





Early ART associated with
higher CD4 2.8 yr after
cessation
25% of treated group
controlled RNA 2.8 yr
after cessation
















presumed transmitters >3 m
after cessation.
Rosenberg et al103 3 class regime, most within
72 h of diagnosis with STI if




cells and stable T helper cells
responses, suggesting a
functional immune responses




were able to achieve at
least a transient steady
state off therapy with
viral load below 5000
RNA copies per
milliliter
Rosenberg et al104 ART initiated during acute/
early infection, interrupted at




All subjects had “relatively
healthy CD4” counts
Med viral set points
(defined as average of all
measured VL after ART)
lower in all subjects as
compared with historical
controls (MACS)











Seng et al106 ART initiated during PHI for






and B) or E
Rapid CD4 decline in first 5
m after cessation, more
slowly thereafter. More rapid
gains in CD4 during ART
—




























RI Immunological Outcomes Virological Outcomes
associated with greater loss
after cessation




or F or L or
(G and J)
Time to CD4+ count <350
was 65 wk longer with 48-wk
course versus SOC
48-wk course conferred
lower RNA levels 36 wk
after cessation versus
SOC
Steingrover et al108 3 or 4 class regimen,




(B or H)) or
E
Significantly greater drop in
CD4+ cell count in later
initiators within first 4 wk; no
difference after 4 wk




Steingrover et al109 3 or more class regimens;




(B or H)] or
E
No significant difference in
rate of CD4 decline between
2 groups
Early transient ART
associated with a initial
but transient lowering of
viral set point, defined as
7 wk after
seroconversion or 7 wk
after ART interruption
Stekler et al50 40: ART <30 d; 82: ART 31–











increased CD4+ cell count,
enhanced differentiation of
HIV-specific CD8+ T cells
from effector memory to
effector cells at week 24, and
higher virus-specific
interferon-g+ CD8+ T-cell
responses after viral rebound
at 48 wk. But by 6 m no
difference in CD4 count
Treatment resulted in
suppression of viremia at
48 wk but no difference
at 6 mth after
termination





CD38++ cell counts within 2
wk of ART and continued to
fall in suppressed patients
80% suppressed on
therapy, most of whom
(67%) continued to have
falling CD8+/CD38++
cell counts
Vinikoor et al112 ART initiation within 45 d of
AHI diagnosis; for those
suppressed for 96 wk
AHI: A and
B
% of CD8+ cells with
CD38++HLA- DR+ decreased
from 72.6% to 15.6% in 96




lower activation at 96 wk
Volberding et al113 4 class regimen in acute or
recent HIV with interruption











activated CD8+ T cells, naive
and memory CD4þ and CD8þ
T cells, and absolute CD4þ
and CD8þ T-cell counts were
not associated with primary
end point success
End point of viral
suppression for 24 wk
postinterruption
achieved at same rate in
both arms
Wyl et al114 Elective std 1st line; option








— VL (both plasma and cell
associated) lower in
treated versus untreated
controls 1 yr after ART
cessation, but no
difference by 3 yrs
Younes et al115 1 yr of ART initiated at 5
different time points up to 18
mth postseroconversion
SC: (A and
B) or G or





Tm cells. Later ART limits
HIV-specific CD4 T-cell
responses. ART initiation
between 3–18 m show brisk
—




























RI Immunological Outcomes Virological Outcomes
and broad HIV-specific CD4
T-cell responses
A, enzyme immunoassay (EIA) negative; AUS, Australia; AHI, acute HIV infection; B, detectable plasma HIV RNA; C, EIA positive; D, Western
blot negative or indeterminate; E, negative and positive EIA result within 12 months; ER, Europe; F, detuned nonreactive EIA; G, acute retroviral
syndrome symptoms, most commonly including fever, malaise, headache, lethargy, and malaise; H, detectable p24 antigen; I, negative gp120
avidity; J, Western Blot positive; K, duration from estimated date of infection based on at least one of the following (1) onset of ARS symptoms,
(2) a documented high-risk exposure, or (3) estimated date of infection determined by laboratory methods; L, evolving titer-positive HIV antibody
test; M, Fiebig acute HIV staging (<30 days postinfection); NA, North America; PHI, primary HIV infection; RI, recent infection; SC,
seroconversion.
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